Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Short Interest Up 13.5% in June

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) was the recipient of a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 94,400 shares, a growth of 13.5% from the May 30th total of 83,200 shares. Currently, 1.1% of the company’s shares are short sold. Based on an average trading volume of 18,800 shares, the short-interest ratio is presently 5.0 days.

Shares of NASDAQ CPIX opened at $5.75 on Tuesday. The company has a current ratio of 2.07, a quick ratio of 1.67 and a debt-to-equity ratio of 0.36. The firm’s fifty day moving average price is $6.22. The company has a market cap of $88.10 million, a price-to-earnings ratio of -47.92 and a beta of 0.14. Cumberland Pharmaceuticals has a twelve month low of $4.83 and a twelve month high of $7.00.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported $0.09 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.22. The business had revenue of $11.90 million during the quarter, compared to analyst estimates of $10.70 million. Cumberland Pharmaceuticals had a positive return on equity of 2.54% and a negative net margin of 10.57%. On average, equities research analysts anticipate that Cumberland Pharmaceuticals will post 0.28 earnings per share for the current year.

In related news, Director Gordon R. Bernard sold 13,264 shares of the firm’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $6.31, for a total transaction of $83,695.84. Following the completion of the sale, the director now directly owns 86,319 shares of the company’s stock, valued at approximately $544,672.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gordon R. Bernard sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $6.36, for a total value of $25,440.00. Following the sale, the director now directly owns 86,319 shares of the company’s stock, valued at $548,988.84. The disclosure for this sale can be found here. Over the last three months, insiders have purchased 19,132 shares of company stock valued at $117,367 and have sold 36,835 shares valued at $231,252. 39.38% of the stock is currently owned by company insiders.

A number of equities research analysts recently issued reports on CPIX shares. Zacks Investment Research raised Investors Real Estate Trust Reit from a “sell” rating to a “hold” rating in a research note on Thursday, May 23rd. TheStreet raised Medpace from a “c” rating to a “b-” rating in a research note on Wednesday, April 10th.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.

Recommended Story: Quiet Period

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.